Welcome to the first issue of Freelite® InSite, an e-newsletter to help you stay fully aware of the status of serum free light chain testing for diagnosis and monitoring of Multiple Myeloma. Four times a year we will review the latest publications and conferences and include articles aimed at discussing key areas of clinical relevance.

 

In this first issue you will find an interview with Dr Robert Kyle, discussing how the Mayo Clinic uses the Freelite serum free light chain assay.

 

I will be very happy to hear from you on what you would like included to help make this an even more valuable source of information for you. 

 

Kind regards

 

 

 

Barbara Maniglia

Business Development Manager - Freelite

2008 Issue 1

If you no longer wish to receive this newsletter, please Click here to unsubscribe.

1. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

Marie-Christine Kyrtsonis et al. British Journal of Haematology 2007, 137:240-243

 

Click here for a summary of this publication.

 

2. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor         prognosis

Frits van Rhee et al. Blood 2007, 110(3):827-832

 

Click here for a summary of this publication.

 

3. Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In Vitro and In Vivo Studies

Colin A. Hutchinson et al JASN March 2007:Vol18:No.3 pp. 886-895

 

Click here for a summary of this publication.

 

4. Eliminate urine testing during initial investigations for monoclonal          gammopathies

Fiona Kilvington, Clinical Laboratory International May 2007:3

 

Click here to view this publication

Publication review – keep up to date with recent publications

Barbara Maniglia

The XIth International Workshop on Multiple Myeloma and IVth          Waldenstroms Workshop, Kos, June 25-30 2007

Click here to view webcasts of the meeting presentations.

 

The XIIth International Workshop on Multiple Myeloma and Vth Waldenstroms   Workshop, meeting will be held in February 2009 in Delhi, India. 2,000 delegates are expected.

 

Webcast on Multiple Myeloma: Clinical and Analytical Advances. Dr Durie and Dr Katzmann

If you didn't make it to the American Association of Clinical Chemistry meeting in July 2007, you can still hear what Drs Durie and Katzmann had to say on this topic. 

Click here to view webcast. 

Exhibitions and Meetings - Catching up and planning ahead

Text Box: Interview with Robert Kyle MD, Mayo Clinic, USA.
Click here

If you have a friend or colleague who you feel would benefit from receiving this newsletter then please forward this to them.

Find out more about serum free light chains at www.freelite.co.uk

Refer a friend/colleague

Having problems viewing or printing this newsletter? Click here to view online.

The Binding Site Ltd
PO Box 11712, Birmingham, B14 4ZB, U.K.

Registered in England Number 1644144

Healthcare professional viewpoint

Þ Review of ASH, 8 - 11 December 2007

Þ Interview with Brian Durie MD - Senior Advisor for Hematologic Malignancies and National Program Director for Multiple Myeloma at Aptium College.

What’s in Issue 2

We need your permission to send you future issues - please Click here to register.

Received this from a colleague?

Text Box: Dr Colin Hutchison, Research Fellow, Renal Unit, Queen Elizabeth Medical Centre, Birmingham
‘Free light chains (FLCs) can result in a diversity of renal injuries in patients with plasma cell dyscrasias. Freelite provides a sensitive and rapid way of identifying monoclonal FLCs in patients presenting with acute or chronic renal impairment. A great advantage is the ability to identify FLCs in the serum removing the dependency on urine samples. The ease of measurement of serum FLCs with Freelite has been influential in allowing our ongoing research into treatment strategies for patients with cast nephropathy.’